Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (Nasdaq: DXR) reported significant achievements in its recent shareholder update. On February 4, 2022, Daxor celebrated its Nasdaq listing with a ceremonial bell ringing in Times Square. The company achieved a 70.6% revenue increase in 2021 compared to the previous year, reporting a net asset value of $21.15 million. Daxor plans to launch new point-of-care blood volume systems in 2022, enhancing market capabilities. The company also made strides in clinical outcomes and research with NIH support, marking a pivotal year for growth and innovation.
Daxor Corporation (Nasdaq: DXR) reported impressive financial results for fiscal 2021, achieving a 70.6% increase in unaudited revenues from its operating division, which includes the BVA diagnostic systems. The company's net asset value (NAV) rose to $5.24 per share, marking a 34.7% increase from $3.89 in 2020. The growth is attributed to new client contracts, including the U.S. Department of Defense. Daxor also announced advancements in its next-generation blood volume analysis technology and secured a $750,000 contract for further development.
Daxor Corporation (Nasdaq: DXR) has revealed new data on the clinical utility of its BVA-100 blood test for heart failure patients, published in the Journal of Cardiac Failure. The study indicates a disconnect between pressure and blood volume metrics, emphasizing the importance of blood volume assessment over pressure monitoring in managing heart failure. Authors noted that volume-based strategies may enhance patient care. With over 100 peer-reviewed studies supporting its efficacy, Daxor's technology is positioned as a critical tool in addressing heart volume management.
Daxor Corporation (Nasdaq: DXR) commenced trading on the NASDAQ Capital Markets on February 2, 2022. To celebrate, CEO Michael Feldschuh will ring the Opening Bell on February 4, 2022. This milestone is expected to enhance the company's visibility, trading liquidity, and attract institutional investors. Daxor specializes in blood volume measurement technology, with over 60,000 tests conducted using their FDA-cleared BVA-100. Ongoing trials in heart failure and COVID-19 are supported by the NIH and the Department of Defense.
Daxor Corporation (NYSE: DXR) has appointed Caleb DesRosiers to its Board of Directors, effective January 18, 2022. DesRosiers, a Senior Principal at Valuate Healthcare Consultancy, brings extensive strategic and regulatory experience to the role, having previously worked with CMS and in the life sciences sector at Pfizer and Roche. CEO Michael Feldschuh expressed that DesRosiers' expertise will support Daxor's vision of optimal blood volume for patients. Daxor is a leader in blood volume measurement technology with its FDA-cleared BVA-100 Blood Volume Analyzer.
Daxor Corporation (NYSE: DXR) has announced the transfer of its common stock listing from the New York Stock Exchange - American to The Nasdaq Capital Market, effective February 2, 2022. CEO Michael Feldschuh stated that this move is expected to enhance stock visibility, trading liquidity, and attract institutional investors. Daxor is recognized for its BVA-100® technology, the first FDA-cleared diagnostic blood test for quantifying blood volume. The company aims to advance healthcare through optimal fluid management.
Oak Ridge, TN, Jan. 06, 2022 - Daxor, the leader in blood volume measurement technology, announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 a.m. ET on January 10. Key highlights will include updates on the new patent award and development of BVA-100. Daxor aims to improve healthcare through advanced blood volume analysis, focusing on enhancing treatment strategies in various medical fields.
Daxor Corporation (NYSE: DXR) announced the completion of patient enrollment and commencement of data analysis for a multi-center observational study utilizing the BVA-100 blood volume measurement technology in hospitalized COVID-19 patients. Conducted by NYU Langone Health and others, the study aims to investigate fluid imbalances in COVID-19 patients, revealing significant capillary damage and blood volume deficits. The results are expected to enhance treatment strategies and outcomes for critically ill patients.
Daxor Corporation (NYSE: DXR) has received a new patent (U.S. Patent No. 11,204,356 B2) for its innovative blood volume analysis technology, aimed at enhancing treatment decisions across various medical conditions. This patent protects a clinical guidance system designed for optimal fluid management, combining unique volume metrics with treatment pathways. CEO Michael Feldschuh emphasized that this marks a significant milestone in advancing healthcare. Daxor is actively developing solutions supported by the National Institutes of Health, aiming to improve outcomes for conditions like heart failure.
Daxor Corporation (NYSE: DXR) presented new studies validating its BVA-100 blood test at the American Heart Association Scientific Sessions. The test helps identify heart failure patient-specific phenotypes and detect true anemia. The first study on patients with left ventricular assist devices revealed blood volume variations, while the second study found traditional hematocrit measures lack sensitivity for true anemia. The findings support the increasing adoption of BVA technology in optimizing heart failure management.